Glioblastoma multiforme: State of the art and future therapeutics

Aguilar, 2012, Curr Treat Options Oncol, The spectrum of vaccine therapies for patients with glioblastoma multiforme, 437

Ahmed, 2011, Mol Ther, Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma, 1714

Ahmed, 2011, Mol Pharm, A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma, 1559

Anton, 2012, Hematol Oncol Clin North Am, Glioblastoma multiforme: Overview of current treatment and future perspectives, 825

Ardon, 2010, Pediatr Blood Cancer, Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours, 519

Ardon, 2010, J Neurooncol, Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study, 261

Arjona, 2006, Curr Mol Med, Early genetic changes involved in low-grade astrocytic tumor development, 645

Bai, 2011, Trends Mol Med, Molecular targeting of glioblastoma: Drug discovery and therapies, 301

Balss, 2008, Acta Neuropathol, Analysis of the IDH1 codon 132 mutation in brain tumors, 597

Bao, 2006, Nature, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, 756

Barba, 1989, J Neurosurg, Intratumoral LAK cell and interleukin-2 therapy of human gliomas, 175

Batchelor, 2010, J Clin Oncol, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, 2817

Bello, 2001, Neurosurgery, Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery, 380

Beltinger, 1999, Proc Natl Acad Sci U S A, Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases, 8699

Beroukhim, 2007, Proc Natl Acad Sci U S A, Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma, 20007

Bigner, 1995, J Neurooncol, Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′) 2--a preliminary report, 109

Blancher, 1993, Eur Cytokine Netw, Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells, 331

Boiardi, 1994, Cancer Immunol Immunother, Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients, 193

Brady, 1992, Int J Radiat Oncol Biol Phys, Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial, 225

Brennan, 2009, PloS One, Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations, e7752

Brown, 2008, J Clin Oncol, Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177, 5603

Buchschacher, 2000, Blood, Development of lentiviral vectors for gene therapy for human diseases, 2499

Cahoy, 2008, J Neurosci, A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function, 264

Calabrese, 2007, Cancer Cell, A perivascular niche for brain tumor stem cells, 69

Cancer, 2008, Nature, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, 1061

Candolfi, 2009, Clin Cancer Res, Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity, 4401

Caruso, 2004, Neuro Oncol, Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer, 236

Castro, 2011, Curr Gene Ther, Gene therapy and targeted toxins for glioma, 155

Chambers, 1995, Proc Natl Acad Sci U S A, Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma, 1411

Chang, 2011, J Clin Neurosci, A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma, 1048

Chaudhry, 2001, Histopathology, Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas, 409

Chen, 2012, Nature, A restricted cell population propagates glioblastoma growth after chemotherapy, 522

Chen, 2012, Cell, Malignant glioma: Lessons from genomics, mouse models, and stem cells, 36

Chinot, 2007, J Clin Oncol, Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide, 1470

Chinot, 2011, Adv Ther, AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme, 334

Chiocca, 2004, Mol Ther, A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting, 958

Choi, 2009, Brain Pathol, EGFRvIII-targeted vaccination therapy of malignant glioma, 713

Chow, 2011, Immunotherapy, Cellular immunotherapy for high-grade glioma, 423

Clarke, 2010, Arch Neurol, Recent advances in therapy for glioblastoma, 279

Cloughesy, 2006, J Clin Oncol, Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study, 3651

Cloughesy, 2008, PLoS Med, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma, e8

Combs, 2006, BMC Cancer, Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: Study protocol, 133

Corey, 1986, Diagn Microbiol Infect Dis, Laboratory diagnosis of herpes simplex virus infections.Principles guiding the development of rapid diagnostic tests, 111

Curtin, 2009, PLoS Med, HMGB1 mediates endogenous TLR2 activation and brain tumor regression, e10

Cutter, 2006, Expert Rev Anticancer Ther, Gene therapeutics: The future of brain tumor therapy?, 1053

Day ED, Lassiter S, Woodhall B, Mahaley JL, Mahaley MS Jr. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res 1965;25:773-8.

Day, 2012, Neurosurg Clin N Am, Clinical trials of small molecule inhibitors in high-grade glioma, 407

De, 2008, Clin Cancer Res, Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme, 3098

Debinski, 2000, Mol Med, Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen, 440

Debinski, 1999, Int J Oncol, Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme, 481

Debinski, 1996, J Biol Chem, Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells, 22428

Debinski, 1995, Clin Cancer Res, Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin, 1253

Debinski, 2000, J Neurooncol, Expression of a restrictive receptor for interleukin 13 is associated with glial transformation, 103

Del, 2010, Curr Opin Mol Ther, Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme, 741

Dembinski, 2010, Cancer Gene Ther, Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells, 289

Dillman, 2011, Cancer Biother Radiopharm, Cancer immunotherapy, 1

Dillman, 2009, J Immunother, Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma, 914

Dillman, 2004, J Immunother, Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma, 398

Dirks, 2008, J Clin Oncol, Brain tumor stem cells: Bringing order to the chaos of brain cancer, 2916

Drablos, 2004, DNA Repair (Amst), Alkylation damage in DNA and RNA--repair mechanisms and medical significance, 1389

Dresemann, 2005, Ann Oncol, Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series, 1702

Dvorak, 2002, J Clin Oncol, Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, 4368

Ehtesham, 2004, Cancer Control, Recent progress in immunotherapy for malignant glioma: Treatment strategies and results from clinical trials, 192

El-Aneed, 2004, J Control Release, An overview of current delivery systems in cancer gene therapy, 1

Eller, 2005, Neurosurgery, Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo, 155

Ferguson, 2010, Discov Med, Crossing the boundaries: Stem cells and gene therapy, 192

Ferrara, 2005, Oncology, VEGF as a therapeutic target in cancer, 11

Ferrara, 2009, Eur Cytokine Netw, VEGF-A: A critical regulator of blood vessel growth, 158

Ferrara, 2003, Nat Med, The biology of VEGF and its receptors, 669

Floeth, 2001, Cancer Gene Ther, Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma, 843

Forsyth, 2008, Mol Ther, A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas, 627

Friedman, 2009, J Clin Oncol, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, 4733

Fueyo, 2003, J Natl Cancer Inst, Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway, 652

Fueyo, 2000, Oncogene, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo, 2

Fujisawa, 2000, Lab Invest, Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas, 65

Fukai, 2008, Cancer Sci, Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III, 2062

Furnari, 2007, Genes Dev, Malignant astrocytic glioma: Genetics, biology, and paths to treatment, 2683

Galanis, 2005, J Clin Oncol, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study, 5294

Geoerger, 2002, Cancer Res, Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts, 764

Germano, 2003, J Neurooncol, Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas, 279

Gerson, 2004, Nat Rev Cancer, MGMT: Its role in cancer aetiology and cancer therapeutics, 296

Gilbert M, editor RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). 2013 ASCO Annual Meeting; 2013; Chicago.

Gomez-Manzano, 2012, Handb Clin Neurol, Gene therapy, 331

Grandi, 2009, Expert Rev Neurother, Design and application of oncolytic HSV vectors for glioblastoma therapy, 505

Haas-Kogan, 2005, J Natl Cancer Inst, Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib, 880

Han, 2007, J Gene Med, Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy, 99

Harsh, 2000, J Neurosurg, Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study, 804

Hart, 2008, Cochrane Database Syst Rev, Chemotherapeutic wafers for High Grade Glioma, CD007294

Hasselbalch, 2010, Neuro Oncol, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial, 508

Hasselbalch, 2010, Cancer Invest, Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling, 775

Hawasli, 2013, Neurosurgery, Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: Single-institution series, 1007

Hayes, 2001, Crit Rev Oncol Hematol, Adoptive cellular immunotherapy for the treatment of malignant gliomas, 31

Hayes, 1995, Cancer, Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma, 840

Hegi, 2005, N Engl J Med, MGMT gene silencing and benefit from temozolomide in glioblastoma, 997

Heimberger, 2009, Expert Opin Biol Ther, The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients, 1087

Holladay, 1996, J Neurooncol, Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma, 179

Hoover, 2010, Neuroimaging Clin N Am, Clinical trials in brain tumor surgery, 409

Immonen, 2004, Mol Ther, AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study, 967

Iwami, 2010, Neurol Med Chir, Gene therapy for high-grade glioma, 727

Izquierdo, 1997, Acta Neurochir Suppl, Gene therapy in brain tumours: Implications of the size of glioblastoma on its curability, 111

Izquierdo, 1996, Gene Ther, Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy, 491

Jacobs, 1999, Neoplasia, HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part I.HSV-1 structure, replication and pathogenesis, 387

Jacobs, 1999, Neoplasia, HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part II.Vector systems and applications, 402

Jacobs, 1986, Cancer Res, Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial, 2101

Jain, 2007, Nat Rev Neurosci, Angiogenesis in brain tumours, 610

Joshi, 2001, Cancer Res, In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures, 8058

Kahn, 1998, J Mag Reson Imaging, In vivo MRI thermometry using a phase-sensitive sequence: Preliminary experience during MRI-guided laser-induced interstitial thermotherapy of brain tumors, 160

Kaina, 2007, DNA Repair (Amst), MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents, 1079

Kalofonos, 1989, J Nucl Med, Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase, 1636

Kamoun, 2009, J Clin Oncol, Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice, 2542

Kanaly, 2010, Neurosurg Clin N Am, Clinical applications of a peptide-based vaccine for glioblastoma, 95

Kang, 2008, J Neurooncol, Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety, 113

Kangasniemi, 2004, Lasers Surg Med, Thermal therapy of canine cerebral tumors using a 980 nm diode laser with MR temperature-sensitive imaging feedback, 41

Kendall, 2008, Stem Cells, Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling, 1575

Kikuchi, 2004, J Immunother, Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12, 452

Kirson, 2007, Proc Natl Acad Sci U S A, Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors, 10152

Kitahara, 1987, J Neurooncol, Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor, 329

Kleihues, 1999, Neuro Oncol, Primary and secondary glioblastomas: From concept to clinical diagnosis, 44

Kootstra, 2003, Annu Rev Pharmacol Toxicol, Gene therapy with viral vectors, 413

Kranzler, 2009, Curr Gene Ther, Stem cells as delivery vehicles for oncolytic adenoviral virotherapy, 389

Kreisl, 2009, J Clin Oncol, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, 740

Kroeger, 2010, Discov Med, Gene therapy and virotherapy: Novel therapeutic approaches for brain tumors, 293

Kruse, 1997, Cancer Immunol Immunother, Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2, 77

Kunwar, 2010, Neuro Oncol, Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma, 871

Kunwar, 2007, J Clin Oncol, Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group, 837

Latchman, 2001, Gene, Gene delivery and gene therapy with herpes simplex virus-based vectors, 1

Lee, 2006, Cancer Cell, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, 391

Leibel, 1987, J Neurosurg, Radiation therapy for neoplasms of the brain, 1

Lewis, 1994, J Virol, Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus, 510

Li, 2010, J Neurosurg, A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme, 192

Li, 2010, Toxins, Targeted toxins in brain tumor therapy, 2645

Liau, 2005, Clin Cancer Res, Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment, 5515

Lillehei, 1991, Neurosurgery, Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy, 16

Long, 1998, Hum Gene Ther, Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells, 1165

Long, 1999, Hum Gene Ther, Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy, 733

Luptrawan, 2008, Rev Recent Clin Trials, Dendritic cell immunotherapy for malignant gliomas, 10

Mahaley MS Jr, Mahaley JL, Day ED. The localization of radioantibodies in human brain tumors. II. Radioautography. Cancer Res 1965;25:779-93.

Markert, 2009, Mol Ther, Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM, 199

Markert, 2000, Gene Ther, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial, 867

Martinez, 2009, Epigenetics, A microarray-based DNA methylation study of glioblastoma multiforme, 255

McGirt, 2009, J Neurosurg, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme, 583

Mellinghoff, 2007, Clin Cancer Res, PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors, 378

Merchant, 1988, Cancer, Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2, 665

Mesnil, 2000, Cancer Res, Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication, 3989

Mintz, 2003, J Neurooncol, Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma, 117

Mintz, 2002, Neoplasia, IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13, 388

Mischel, 2003, Oncogene, Identification of molecular subtypes of glioblastoma by gene expression profiling, 2361

Mitchell, 2008, Immunol Rev, Immunotherapy of malignant brain tumors, 70

Mitchell, 2009, Neurotherapeutics, Toward effective immunotherapy for the treatment of malignant brain tumors, 527

Mohanam, 1994, J Neurooncol, Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor, 153

Mohyeldin, 2012, Cancer J, Gene and viral therapy for glioblastoma: A review of clinical trials and future directions, 82

Msaouel, 2009, Curr Opin Mol Ther, Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview, 43

Mueller, 2011, J Neurooncol, Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study, 267

Murat, 2008, J Clin Oncol, Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma, 3015

Nakamura, 2000, J Neuropathol Exp Neurol, Loss of heterozygosity on chromosome 19 in secondary glioblastomas, 539

Neyns, 2011, J Neurooncol, Phase II study of sunitinib malate in patients with recurrent high-grade glioma, 491

Neyns, 2009, Ann Oncol, Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma, 1596

Nobusawa, 2009, Clin Cancer Res, IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas, 6002

Ohgaki, 2004, Cancer Res, Genetic pathways to glioblastoma: A population-based study, 6892

Ohgaki, 2013, Clin Cancer Res, The definition of primary and secondary glioblastoma, 764

Ohgaki, 2007, Am J Pathol, Genetic pathways to primary and secondary glioblastoma, 1445

Ostman, 2004, Cytokine Growth Factor Rev, PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma, 275

Parker, 2000, Proc Natl Acad Sci U S A, Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors, 2208

Parsons, 2008, Science, An integrated genomic analysis of human glioblastoma multiforme, 1807

Patel, 2012, Expert Opin Investig Drugs, Molecular targeted therapy in recurrent glioblastoma: Current challenges and future directions, 1247

Peereboom, 2010, J Neurooncol, Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme, 93

Pelloski, 2006, Clin Cancer Res, Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma, 3935

Perry, 2012, Neurol Res Int, Novel therapies in glioblastoma, 428565

Phillips, 2006, Cancer Cell, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, 157

Piccirillo, 2006, Nature, Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells, 761

Pichlmeier, 2008, Neuro Oncol, Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients, 1025

Pitter, 2011, PloS One, Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma, e14545

Plautz, 1998, J Neurosurg, Systemic T cell adoptive immunotherapy of malignant gliomas, 42

Plautz, 2000, Clin Cancer Res, T cell adoptive immunotherapy of newly diagnosed gliomas, 2209

Pollard, 2009, Cell Stem Cell, Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens, 568

Prados, 2009, J Clin Oncol, Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma, 579

Prados, 2006, Neuro Oncol, Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma, 67

Prados, 2003, J Neurooncol, Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I/II multi-institutional trial, 269

Prasad, 2011, Neuro Oncol, Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide, 384

Presta, 1997, Cancer Res, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, 4593

Prins, 2011, Clin Cancer Res, Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy, 1603

Puri, 1999, Toxicol Pathol, Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma, 53

Quattrocchi, 1999, J Neurooncol, Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas, 141

Rahmathulla, 2013, OncoTargets Ther, Bevacizumab in high-grade gliomas: A review of its uses, toxicity assessment, and future treatment challenges, 371

Rainov, 2000, Hum Gene Ther, A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, 2389

Rainov, 2000, Gene Ther, Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme, 1853

Rainov, 2003, J Neurooncol, Clinical trials with retrovirus mediated gene therapy--what have we learned?, 227

Raizer, 2010, Neuro Oncol, A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy, 95

Raizer, 2010, Neuro Oncol, A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas, 87

Ram, 1997, Nat Med, Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells, 1354

Rand, 2000, Clin Cancer Res, Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma, 2157

Raymond, 2008, J Clin Oncol, Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study, 4659

Reardon, 2009, Br J Cancer, Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma, 1995

Reardon, 2009, Cancer, Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma, 2188

Reardon, 2005, J Clin Oncol, Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme, 9359

Reardon, 2008, J Clin Oncol, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, 5610

Reardon, 2008, Expert Opin Investig Drugs, Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme, 1225

Reardon, 2011, J Neurooncol, Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma, 621

Reijneveld, 2000, J Neurol, Angiogenesis in malignant primary and metastatic brain tumors, 597

Ricci-Vitiani, 2010, Nature, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, 824

Rich, 2004, J Clin Oncol, Phase II trial of gefitinib in recurrent glioblastoma, 133

Riva, 1995, Cancer Res, Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: Comparison of the results obtained in recurrent and newly diagnosed tumors, 5952

Rustamzadeh, 2006, Int J Cancer, Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice, 2594

Rustamzadeh, 2007, Int J Cancer, Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice, 411

Rustamzadeh, 2003, J Neurooncol, Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme, 63

Rustamzadeh, 2006, J Neurooncol, Immunotoxin pharmacokinetics: A comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13, 257

Sampson, 2003, J Neurooncol, Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors, 27

Sampson, 2008, Semin Immunol, Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma, 267

Sampson, 2009, Mol Cancer Ther, An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme, 2773

Sampson, 2010, J Clin Oncol, Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma, 4722

Sandmair, 2000, Hum Gene Ther, Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses, 2197

Sathornsumetee, 2007, Cancer, Molecularly targeted therapy for malignant glioma, 13

Scaringi, 2012, Anticancer Res, Integrin inhibitor cilengitide for the treatment of glioblastoma: A brief overview of current clinical results, 4213

Schmidt, 1999, Int J Cancer, Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis, 10

Schwarzmaier, 2005, J Magn Reson Imaging, MR-guided laser irradiation of recurrent glioblastomas, 799

Schwarzmaier, 2006, Eur J Radiol, MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: Preliminary results in 16 patients, 208

Schwarzmaier, 1998, J Magn Reson Imaging, Treatment planning for MRI-guided laser-induced interstitial thermotherapy of brain tumors--the role of blood perfusion, 121

Sebolt-Leopold, 2004, Nat Rev Cancer, Targeting the mitogen-activated protein kinase cascade to treat cancer, 937

Shah, 2003, J Neurooncol, Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas, 203

Shai, 2003, Oncogene, Gene expression profiling identifies molecular subtypes of gliomas, 4918

Shand, 1999, Hum Gene Ther, A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir.GLI328 European-Canadian Study Group, 2325

Shapiro, 1989, J Neurosurg, Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma.Brain Tumor Cooperative Group Trial 8001, 1

Shaw, 2006, Nature, Ras, PI(3) K and mTOR signalling controls tumour cell growth, 424

Silva, 2008, Arterioscler Thromb Vasc Biol, Integrins: The keys to unlocking angiogenesis, 1703

Singh, 2003, Cancer Res, Identification of a cancer stem cell in human brain tumors, 5821

Singh, 2004, Nature, Identification of human brain tumour initiating cells, 396

Sloan, 2013, J Neurosurg, Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: Clinical article, 1202

Sloan, 2000, Neurosurg Focus, Adoptive immunotherapy in patients with recurrent malignant glioma: Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes, e9

Smitt, 2003, Mol Ther, Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir, 851

Son, 2009, Cell Stem Cell, SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma, 440

Stiles, 2008, Neuron, Glioma stem cells: A midterm exam, 832

Stummer, 2006, Lancet Oncol, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial, 392

Stupp R, editor. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. 2013 ASCO; 2013; Chicago.

Stupp, 2009, Lancet Oncol, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, 459

Stupp, 2010, J Clin Oncol, Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma, 2712

Stupp, 2006, Oncologist, Changing paradigms--an update on the multidisciplinary management of malignant glioma, 165

Stupp, 2005, N Engl J Med, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, 987

Sun, 2006, Cancer Cell, Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain, 287

Teicher, 2011, Clin Cancer Res, Antibody conjugate therapeutics: Challenges and potential, 6389

Terada, 2006, Gene Ther, Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models, 705

Thomas, 2012, Cancer J, Immunotherapy for the treatment of glioblastoma, 59

Tobias, 2013, J Neurol Neurosurg Psychiatry, The art of gene therapy for glioma: A review of the challenging road to the bedside, 213

Todhunter, 2004, Protein Eng Des Sel, A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model, 157

Todo, 2001, Proc Natl Acad Sci U S A, Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing, 6396

Trask, 2000, Mol Ther, Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors, 195

Tsuboi, 2003, Clin Cancer Res, Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas, 3294

Tsurushima, 1999, Jpn J Cancer Res, Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes, 536

Uhm, 2011, Int J Radiat Oncol Biol Phys, Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074, 347

Ulasov, 2008, J Med Virol, Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy, 1595

Ulasov, 2007, Hum Gene Ther, Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma, 589

Vallera, 2002, J Natl Cancer Inst, Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT, 597

van, 2009, J Clin Oncol, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034, 1268

van, 2009, J Clin Oncol, MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951, 5881

Van, 2009, Brain Pathol, Dendritic cell therapy of high-grade gliomas, 694

Van, 2004, Semin Oncol, Emerging molecular therapies for brain tumors, 38

Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010;2010.

Veeravagu, 2008, Clin Cancer Res, Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme, 7330

Verhaak, 2010, Cancer Cell, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, 98

Villalva, 2012, Int J Mol Sci, O6-Methylguanine-Methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions, 6983

Vredenburgh, 2007, Clin Cancer Res, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, 1253

Vredenburgh, 2007, J Clin Oncol, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, 4722

Vredenburgh, 2012, Int J Radiat Oncol Biol Phys, Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme, 58

Vredenburgh, 2011, Clin Cancer Res, The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma, 4119

Wainwright, 2012, Expert Opin Emerg Drugs, Recent developments on immunotherapy for brain cancer, 181

Wan, 2007, Oncogene, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism, 1932

Wang, 2010, Stem Cells, Notch promotes radioresistance of glioma stem cells, 17

Wang, 2010, Nature, Glioblastoma stem-like cells give rise to tumour endothelium, 829

Watanabe, 1996, Brain Pathol, Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas, 217

Watanabe, 2009, Am J Pathol, IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas, 1149

Wen, 2008, N Engl J Med, Malignant gliomas in adults, 492

Wen, 2006, Clin Cancer Res, Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08, 4899

Westphal, 2003, Neuro Oncol, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, 79

Wilcox, 2001, J Natl Cancer Inst, Reovirus as an oncolytic agent against experimental human malignant gliomas, 903

Wood, 2000, J Neurooncol, A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma, 113

Xu, 2012, Clin Dev Immunol, Cellular-based immunotherapies for patients with glioblastoma multiforme, 764213

Yajima, 2005, Clin Cancer Res, Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma, 5900

Yamamoto, 1994, Cancer Res, Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo, 3656

Yamanaka, 2008, Trends Mol Med, Cell- and peptide-based immunotherapeutic approaches for glioma, 228

Yamanaka, 2003, Br J Cancer, Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial, 1172

Yan, 2009, N Engl J Med, IDH1 and IDH2 mutations in gliomas, 765

Yu, 2004, Cancer Res, Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma, 4973

Yu, 2001, Cancer Res, Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration, 842

Zhang, 2012, Curr Mol Pharmacol, Temozolomide: Mechanisms of action, repair and resistance, 102

Zhao, 2008, Mol Cancer Res, Neural stem cell tropism to glioma: Critical role of tumor hypoxia, 1819